key papersKey paper
PROMID: octreotide LAR in the control of tumour growth in metastatic midgut neuroendocrine tumours
The PROMID trial was the first to show that a somatostatin analogue, octreotide, slows tumour growth in midgut neuroendocrine tumours, more than doubling the time to progression compared with placebo.
Overview
Phase 3 placebo-controlled trial of 85 treatment-naive patients with well-differentiated metastatic midgut neuroendocrine tumours randomised to octreotide LAR 30 mg monthly or placebo.
Median time to tumour progression was 14.3 versus 6.0 months (hazard ratio 0.34), with the greatest benefit in patients with low hepatic tumour load and resected primary tumours.
Randomised controlled trialChanged practice85 participants
Authors
Rinke A, Müller HH, Schade-Brittinger C, et al.
Published
Findings
- Median time to progression 14.3 vs 6.0 months; hazard ratio 0.34.
- Benefit largest with hepatic tumour load of 10 percent or less.
What it means
Octreotide LAR became a standard first-line antiproliferative therapy for small intestinal neuroendocrine tumours, later joined by lanreotide after CLARINET.
Caveats
- Small trial that closed early for slow accrual.
- No overall survival benefit because of crossover.